Pharmaceuticals leviathan GlaxoSmithkline has extended the offer period for its hostile take-over of US sector peer Human Genome Sciences (HGS).
The offer period had been set to run out at the end of June 7th, but has now been extended to 17:00 (New York City time) on Friday, June 29th.
Glaxo launched a $13 a share offer for HGS after attempts at an agreed takeover were "rejected without discussion".
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The two companies have long worked together and Glaxo's official line is that now is the appropriate time in the evolution of the relationship for the companies to combine.
The extension of the offer period and the fact that HGS continues to trade a little above the Glaxo offer price suggests that HGS shareholders are not convinced by Glaxo's argument.
JH
-
FTSE 100 hits record highs – why is it rising and will we see more gains?Advice UK equities have been described as unloved for a long time but as the FTSE 100 hits new highs, we explain if now is the time to buy British.
-
How to invest in copperIt may be time to invest in copper as the red metal appears poised for a big jump. Dominic Frisby looks at what should investors should buy
